We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FIRMS STILL FALLING SHORT OF POSTMARKETING OBLIGATIONS TO FDA
FIRMS STILL FALLING SHORT OF POSTMARKETING OBLIGATIONS TO FDA
March 12, 2004
Nearly two-thirds of open postmarketing study commitments drugmakers made to FDA after the agency approved their new drug applications (NDAs) or abbreviated new drug applications (ANDAs) have yet to begin, the agency said in an annual report released on Friday.